"It's like an annuity when they find a patient, " says Christopher Raymond, an analyst at Robert W. Baird.

FORBES: Magazine Article

Christopher Raymond, who covers Dendreon for investment bank R.

FORBES: Provenge's Potential

However, RW Baird analyst Christopher Raymond notes that Lucentis may already cost less, in some cases, than the stated pricing due to volume discounts and forthcoming study results may diminish the advantage Regeneron will enjoy by being able to promote more convenient dosing.

FORBES: The Eyes Have It: Can Regeneron Make Roche Blink?